Cargando…

Current Role of Lamivudine Regarding Therapeutic Response and Resistance in Children with Chronic Hepatitis B

PURPOSE: To identify the predictive factors of long-term therapeutic response or resistance to lamivudine treatment in children and adolescents with chronic hepatitis B. METHODS: Eighty one children and adolescents with chronic hepatitis B were included, who received lamivudine treatment for at leas...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hong, Suk Jin, Kim, Yeo Hyang, Choe, Byung-Ho, Park, Hyo Jung, Tak, Won-Young, Kweon, Young-Oh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Society of Pediatric Gastroenterology, Hepatology and Nutrition 2013
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3760700/ https://www.ncbi.nlm.nih.gov/pubmed/24010111 http://dx.doi.org/10.5223/pghn.2013.16.2.80

Ejemplares similares

Evaluating the efficacy of switching from lamivudine plus adefovir to tenofovir disoproxil fumarate monotherapy in lamivudine-resistant stable hepatitis B patients
por: Lee, Heon Ju, et al.
Publicado: (2018)

Hepatitis B surface antigen levels at 6 months after treatment can predict the efficacy of lamivudine-adefovir combination therapy in patients with lamivudine-resistant chronic hepatitis B
por: Kim, Jeong Han, et al.
Publicado: (2014)

Lamivudine plus adefovir combination therapy for lamivudine resistance in hepatitis-B-related hepatocellular carcinoma patients
por: Kim, Jeong Han, et al.
Publicado: (2013)

Comparison of tenofovir plus lamivudine versus tenofovir monotherapy in patients with lamivudine-resistant chronic hepatitis B
por: Park, Chan Ho, et al.
Publicado: (2016)

Adefovir Dipivoxil Alone or in Combination with Ongoing Lamivudine in Patients with Decompensated Liver Disease and Lamivudine-resistant Hepatitis B Virus
por: Kim, Kang Mo, et al.
Publicado: (2005)

Efficacy and safety of entecavir versus lamivudine over 5 years of treatment: A randomized controlled trial in Korean patients with hepatitis B e antigen-negative chronic hepatitis B
por: Lee, Kwan Sik, et al.
Publicado: (2017)

Long-Term Outcomes and Dynamics of Mutants Associated with Lamivudine-Adefovir Rescue Therapy in Patients with Lamivudine-Resistant Chronic Hepatitis B
por: Kim, Jihyun, et al.
Publicado: (2015)

Entecavir+tenofovir vs. lamivudine/telbivudine+adefovir in chronic hepatitis B patients with prior suboptimal response
por: Woo, Hyun Young, et al.
Publicado: (2020)

Treatment of Hepatitis B Virus-Associated Membranous Nephropathy: Lamivudine Era versus Post-Lamivudine Era
por: Moon, Ju-Young, et al.
Publicado: (2012)

A Multicenter Study of the Antiviral Efficacy of Entecavir Monotherapy Compared to Lamivudine Monotherapy in Children with Nucleos(t)ide-naïve Chronic Hepatitis B
por: Lee, Kyung Jae, et al.
Publicado: (2018)

Lamivudine Therapy Exacerbates Bilirubinemia in Patients Underlying Severely Advanced Hepatitis
por: Choi, Young Hee, et al.
Publicado: (2017)

Lamivudine: fading into the mists of time
por: Choi, Jonggi, et al.
Publicado: (2017)

Virologic response is not durable after adefovir discontinuation in lamivudine-resistant chronic hepatitis B patients
por: Jung, Young Kul, et al.
Publicado: (2011)

Efficacy of tenofovir-based rescue therapy for chronic hepatitis B patients with resistance to lamivudine and entecavir
por: Jeon, Hee-Jeong, et al.
Publicado: (2017)

Lamivudine Therapy for Korean Children with Chronic Hepatitis B
por: Koh, Hong, et al.
Publicado: (2007)

Comparison of the clinical outcomes between antiviral-naïve patients treated with entecavir and lamivudine-resistant patients receiving adefovir add-on lamivudine combination treatment
por: Kim, Hong Joo, et al.
Publicado: (2016)

Long-term outcomes of two rescue therapies in lamivudine-refractory patients with chronic hepatitis B: combined lamivudine and adefovir, and 1-mg entecavir
por: Ze, EunYoung, et al.
Publicado: (2014)

Detection of YMDD Motif Mutants by Oligonucleotide Chips in Lamivudine-Untreated Patients with Chronic Hepatitis B Virus Infection
por: Heo, Jeong, et al.
Publicado: (2004)

Efficacy of Lamivudine or Entecavir on Acute Exacerbation of Chronic Hepatitis B
por: Kanda, Tatsuo, et al.
Publicado: (2011)

Entecavir and lamivudine therapy for severe acute chronic hepatitis B
por: LIU, CHANGHONG, et al.
Publicado: (2013)

High Dose of Lamivudine and Resistance in Patients with Chronic Hepatitis B
por: Wani, Hamid Ullah, et al.
Publicado: (2014)

Overlapping Gene Mutations of Hepatitis B Virus in a Chronic Hepatitis B Patient with Hepatitis B Surface Antigen Loss during Lamivudine Therapy
por: Lee, Sun-Young, et al.
Publicado: (2005)

Lamivudine plus adefovir is a good option for chronic hepatitis B patients with viral relapse after cessation of lamivudine treatment
por: Wang, Zhao, et al.
Publicado: (2011)

Combination therapy of lamivudine and adefovir in Japanese patients with chronic hepatitis B
por: Shakado, Satoshi, et al.
Publicado: (2008)

Update on rescue therapies in patients with lamivudine-resistant chronic hepatitis B
por: Chao, Daniel C, et al.
Publicado: (2013)

Lamivudine therapy for chronic hepatitis B in children: a meta-analysis
por: Luo, Aoran, et al.
Publicado: (2019)

Rescue therapy with adefovir in decompensated liver cirrhosis patients with lamivudine-resistant hepatitis B virus
por: Woo, Hyun Young, et al.
Publicado: (2014)

Meta-analysis: Adefovir dipivoxil in combination with lamivudine in patients with lamivudine-resistant hepatitis B virus
por: Chen, En-Qiang, et al.
Publicado: (2009)

Treatment with lamivudine versus lamivudine and thymosin alpha-1 for e antigen-positive chronic hepatitis B patients: a meta-analysis
por: Zhang, Yuan-Yuan, et al.
Publicado: (2009)

Entecavir plus tenofovir versus entecavir plus adefovir in chronic hepatitis B patients with a suboptimal response to lamivudine and adefovir combination therapy
por: Park, Jung Gil, et al.
Publicado: (2015)

Lamivudine treatment for severe acute HBV hepatitis
por: Lisotti, Andrea, et al.
Publicado: (2008)

The Rate of Conversion from Immune-tolerant Phase to Early Immune-clearance Phase in Children with Chronic Hepatitis B Virus Infection
por: Hong, Suk Jin, et al.
Publicado: (2014)

Advanced fibrosis is not a negative pretreatment predictive factor for genotype 2 or 3 chronic hepatitis C patients
por: Lee, Hyun Seok, et al.
Publicado: (2013)

Lamivudine plus adefovir combination therapy versus entecavir monotherapy for lamivudine-resistant chronic hepatitis B: a systematic review and meta-analysis
por: Sheng, Yun-Jian, et al.
Publicado: (2011)

Inflammation Pharmacological Reaction and YMDD Mutational Patterns in Lamivudine Therapeutics Hepatitis B Virus
por: Liu, Hongcan, et al.
Publicado: (2021)

Strategies for treating and managing chronic hepatitis C in children in the direct-acting antiviral era
por: Hong, Suk-Jin, et al.
Publicado: (2020)

Impact of prior lamivudine use on the antiviral efficacy and development of resistance to entecavir in chronic hepatitis B patients
por: Hwang, Joo An, et al.
Publicado: (2015)

Hepatitis B Virus Genotyping Among Chronic Hepatitis B Individuals With Resistance to Lamivudine in Shahrekord, Iran
por: Karimi, Ali, et al.
Publicado: (2014)

Comparison of the efficacy of lamivudine and telbivudine in the treatment of chronic hepatitis B: a systematic review
por: Zhao, Shushan, et al.
Publicado: (2010)

Virologic response and breakthrough in chronic hepatitis B Egyptian patients receiving lamivudine therapy
por: Ismail, Sohair, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_vrc92h26c994so3gs2p1e6ed8o